Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agrostis stolonifera pollen is a biologic allergenic extract derived from the pollen of Agrostis stolonifera, commonly known as creeping bentgrass. Approved by the FDA in 1967 under BLA 101376, this extract is used for both the diagnosis of grass pollen hypersensitivity via skin testing and the treatment of allergic conditions through allergen immunotherapy. The therapeutic mechanism involves the induction of immunological tolerance, characterized by a shift from a Th2-mediated allergic response to a Th1-mediated or regulatory T-cell response, alongside the production of allergen-specific IgG4 blocking antibodies. This process reduces the IgE-mediated release of inflammatory mediators from mast cells and basophils upon subsequent allergen exposure, providing long-term relief for patients with allergic rhinitis, conjunctivitis, and asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agrostis stolonifera pollen.